Kornimate/medical-research-clean huggingface dataset:
tailored approaches to stroke health education

Conditions: Stroke

Summary: the overarching goal of the proposed intervention is to reduce stroke disparities by overcoming pre-hospital barriers related to emergency stroke treatment and facilitating the appropriate response to acute stroke using a novel culturally-tailored and sustainable approach developed by an experienced transdisciplinary team. building on our previous work, in which the investigators have identified barriers to increasing stroke literacy and behavioral intent to call 911, the investigators will develop and evaluate the effectiveness of a novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-minute films (in english and spanish), in minority populations in new york city (nyc). behavioral intent to call 911 will be assessed immediately after viewing the film, 6 months later, and one year later.

stroke is the leading cause of adult disability and costs u.s. taxpayers \>$60 billion annually. interventions designed to educate patients to seek treatment sooner when a stroke occurs may increase low rates of treatment with thrombolysis (current rates 3% national average). thrombolysis can increase the odds of minimal to zero disability from stroke if emergency medical system response times and in-hospital response times are optimized (maximum time from symptom onset to intravenous thrombolysis is 4.5 hours). black and hispanic americans have higher stroke incidence compared to whites and are less likely to receive thrombolysis for acute stroke. the latency to hospital arrival is largely dependent on patients' recognition of stroke symptoms, and immediate presentation to the emergency department. the investigators have found very low stroke literacy rates among blacks and hispanics compared to whites, which may, in part, be responsible for disparities in acute stroke treatment.

Eligibility criteria:
inclusion criteria: 1. no prior history of stroke; 2. high risk (defined as a history of one or more stroke risk factor (hypertension (htn), diabetes, tobacco, abdominal obesity, heart disease, high cholesterol); 3. over age 34 years at onset of intervention (we have selected this age cut off due to the large increase in stroke incidence among minority groups at age 34 ); 4. self-identified as black or hispanic; and 5. member of a church congregation who lives in a household with a telephone. exclusion criteria: 1. participant is unable to give consent; 2. a modified rankin score \> 4 at baseline; 3. history of dementia; and 4. terminal illness, or other medical illness resulting in mortality \< 1 year.

Keywords: stroke community health education minority health healthcare disparities
surgical treatment of aortic stenosis with a next generation surgical aortic valve

Conditions: Aortic Valve Stenosis With Insufficiency; Aortic Valve Stenosis

Summary: the purpose of this clinical investigation is to confirm that the safety and performance of the edwards intuity valve system.

this is a two-phase, non-randomized, prospective, single arm, multi-center clinical investigation. each subject in phase 1 and phase 2 is consented for a period of 5 years. all subjects will be assessed for clinical follow-up at the following intervals: discharge, 1 month, 3 months, 1 year and annually thereafter until 5 years of follow-up is achieved per subject.

Eligibility criteria:
criteria: inclusion criteria: * 18 years or older * aortic stenosis or stenosis-insufficiency of aortic valve requiring a planned replacement as indicated in the preoperative evaluation; * scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, maze procedure, septal myectomy, pacemaker/icd implant and or atrial appendage occlusion/removal. * signed and dated the informed consent form prior to investigation procedures; * geographically stable and agrees to attend follow up assessments at the hospital of surgical services for a maximum of 5 years. exclusion criteria: * pure aortic insufficiency * requires emergency surgery * aneurysm of the aortic root and/or ascending aorta requiring surgical intervention * left ventricular ejection fraction of ≤ 25% * active endocarditis within 3 months prior to the scheduled aortic valve replacement surgery * concomitant valve (mitral, tricuspid, or pulmonic) disease requiring repair with an annuloplasty ring or replacement with prosthesis * prior mitral, tricuspid or pulmonic valve surgery, which included implantation of a bioprosthetic valve, mechanical valve, or annuloplasty ring. * myocardial infarction (mi) within 1 month prior to the scheduled aortic valve replacement surgery * previously implanted with edwards intuity aortic valve; alcohol or drug abuser * disease limiting life expectancy to less than 12 months * pregnant or lactating * currently participating in another drug or device clinical investigation; * documented blood diatheses * requires non-cardiac procedures such as carotid procedures or mediastinal tumor removal * had a stroke or transient ischemic attack (tia) within 6-months prior to scheduled aortic valve replacement surgery * study site pre-operative echocardiographic assessment shows evidence of an intracardiac mass, thrombus, or vegetation * hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days of procedure * documented renal insufficiency as determined by serum creatinine ≥ 200 µmol/l (2.27 mg/dl) at screening or end-stage renal disease requiring chronic dialysis * documented hyperparathyroidism

Keywords: aortic valve replacement
vitamin d3 supplementation and stress fracture occurrence in high-risk collegiate athletes

Conditions: Vitamin D Deficiency; Stress Fracture; Athletic Injuries; Orthopedic Disorder

Summary: the main objective of this study is to find a correlation between vitamin d deficiency and stress fracture occurrences in athletes who participate in high-risk activities. these high-risk athletes undergo elevated bone turnover, which requires adequate levels of vitamin d in order to support bone health. it is hypothesized that providing supplemental treatment to athletes showing lower than normal serum vitamin d levels will decrease the occurrence of stress fractures. by recording the dates and specific occurrences of fractures, it may be possible to correlate injury rates with seasons, providing more supportive data to pre-existing literature. this area of research is lacking in the quantity of prospective studies. previous studies primarily focus on adolescent, elder, or military recruit populations. while literature has shown that vitamin d plays an important role in bone health, there are no previous studies that directly examine vitamin d deficiency and supplemental treatment in conditioned collegiate athlete populations. this study will add to the existing knowledge and will provide a more specific analysis for athletes.

this study will focus on athletes who are at a higher risk of lower extremity stress fractures. specifically, this study will be looking at male and female athletes on the track, cross-country, soccer, and basketball teams at the university of south carolina. during the pre-season physical of each student athlete, serum vitamin d levels will be taken and recorded. there will be a certified nurse to draw the blood samples. this will take place at the university of south carolina athletic department and/or the palmetto health lab at 2 medical park. potentially, every athlete of the given teams will be enrolled in the study unless they choose not to. only subjects showing concentrations below 30 ng/ml, which is indicative of insufficient or deficient levels, will be provided supplemental treatment of 25-(oh) vitamin d. every enrolled subject will be monitored for injury throughout the season. any and all injuries will be positively identified, and any confirmed stress fractures will be recorded. data from prospective seasons will be compared to an incidence percentage of athletes from previous seasons. previous athletes did not receive any vitamin d treatment. these will be used as a control to determine if treatment affected the occurrence of stress fractures. all physicals and tests will be performed at the university of south carolina sports medicine clinic by the sports medicine staff.

Eligibility criteria:
inclusion criteria: * athlete on one of the following teams at local university: men/women track and field, soccer, basketball, and women's cross country. exclusion criteria: * athlete currently diagnosed with a stress fracture * athlete recovering from a lower extremity musculoskeletal injury
reinduction chemotherapy containing carboplatin and paclitaxel with or without epoetin alpha in recurrent platinum sensitive ovarian cancer, cancer of the fallopian tube or peritoneum

Conditions: Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum; Platinum Sensitve Relapse; Anemia

Summary: patients with epithelial ovarian cancer, fallopian tube or peritoneal cancer who receive surgical cytoreduction and platinum/taxane containing chemotherapy have a significant chance of entering complete clinical remission but about 70% will eventually relapse. relapse more than 6 months following first line chemotherapy is regarded as platinum/taxane sensitive disease. reinduction chemotherapy with platinum/taxane is known to be an effective treatment option. therapy induced anemia is a common problem resulting in decrease of quality of life. the rationale of this trail is to evaluate the effects of epoetin alpha on reduction of therapy induced anemia, rate of transfusions and on quality of life.


Eligibility criteria:
inclusion criteria: * relapse longer than 6 months after termination of platinum/taxane based first line chemotherapy * previously histologically confirmed cancer of: ovary, fallopian tube, peritoneum * measurable and evaluable lesions by ultrasound, computer-tomography or mri * performance status ecog \ 60% * normal organ function exclusion criteria: * more than 1 chemotherapy prior enrollment * ongoing treatment with epoetin alpha or related drugs * history of thrombosis or embolism during the past 12 months prior enrollment * ileus * left ventricular failure \> nyha classification \> 2 * ongoing toxicity of any kind (\> ctc grad ii)
effectiveness of the kinesio taping® in muscle activation

Conditions: Muscle Atrophy

Summary: forty-eight female patients will be randomized into three groups to receive the kinesio taping, placebo kinesio taping and control group. the group kinesio taping receive the correct application of the method described. the placebo group will receive a placement without tension. the control group did not receive any form of intervention.

the group kinesio taping receive the correct application of the method described with tension of 40%. the placebo group will receive a placement without tension. the control group did not receive any form of intervention.

Eligibility criteria:
inclusion criteria: * woman * sedentary exclusion criteria: * physically active, * pain * men * musculoskeletal injury in the last six months.

Keywords: kinesio taping muscle activation muscle inhibition
intensive bimanual intervention in cerebral palsy children

Conditions: Cerebral Palsy

Summary: motor disorders related to cerebral palsy are often accompanied by sensory, cognitive, perceptive, communication and behavioural impairments. it has already been shown that intensive bimanual intervention can improve arm movement, but its impact on the spontaneous use of the most affected arm in everyday life remains to be established. this project aims to understand the impacts of an intensive bimanual therapy on uni- and bi-manual motor functions as well as the spontaneous use of the most affected arm. predictive value of neuroimaging variables will also be assessed.

most activities of everyday life require the use of both hands in a coordinated manner. motor disorders related to cerebral palsy lead to activity limitations due to motor function disturbances. it has already been shown that intensive bimanual intervention can improve arm movement, but its impact on the spontaneous use of the most affected arm in everyday life remains to be established. this project aims to understand the impacts of intensive bimanual therapy on the motor functions of both arms (working together or in isolation) as well as on the spontaneous use of the most affected limb. predictive value of neuroimaging variables will also be assessed. thirty children living with cerebral palsy will be recruited over a 5-year period. the intervention consists of a day camp, where a small group of participants will be stimulated (one worker per child) to do activities using both hands 6 hours/day for 10 days. there will be three periods of evaluation (pre-intervention, post-intervention and 6-month follow-up). these evaluation periods consist of neuroimaging assessment, clinical evaluation, robotic evaluation and movement evaluation using inertial control units. the use of more accurate measurements of sensorimotor arm functions using robotic systems will clarify the relationship between measurements of brain function and clinical improvements, to better understand the significant variability observed in response to interventions.

Eligibility criteria:
inclusion criteria: * having a diagnosis of cerebral palsy or spastic hemiparesis encephalopathy * having sensorimotor deficits of one or both upper limb (spastic hemiparesis with a dominance on one side of the body; manual ability classification system (macs) level 1, 2 or 3); * having cognitive capacities to understand and perform task of the study. exclusion criteria: * presenting other significant health problem which may interfere with the requested task or with the clinical intervention; * having botox injection in one or both upper limbs with the 4 months prior to the intervention; * presenting significant uncorrected visual deficits. n.b. having a ferromagnetic implant is not an exclusion criterion, such participant will be eligible but will not perform the mri.

Keywords: intensive bimanual therapy upper limb motor function rehabilitation motor learning accelerometry
a study evaluating the safety, pharmacokinetics, and activity of the combination of cevostamab and elranatamab in participants with relapsed or refractory multiple myeloma (r/r mm)

Conditions: Relapsed or Refractory Multiple Myeloma

Summary: the purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended phase ii dose (rp2d) for the study treatment. the study consists of a safety lead-in stage, and an expansion stage.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * diagnosis of r/r mm per imwg criteria * for female participants of childbearing potential: agreement to remain abstinent or use contraception * for male participants: agreement to remain abstinent or use a condom exclusion criteria: * prior treatment with cevostamab or another agent targeting fragment crystallizable receptor-like 5 (fcrh5) * prior treatment with elranatamab * prior allogeneic stem cell transplantation (sct) * absolute plasma cell count exceeding 500 per milliliter (ml) or 5% of the peripheral blood white cells * diagnosis of waldenström macroglobulinemia or polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, skin changes (poems) syndrome * participants with known history of amyloidosis * history of autoimmune disease * history of confirmed progressive multifocal leukoencephalopathy * peripheral motor polyneuropathy of prespecified grade * known or suspected chronic cytomegalovirus (cmv) and/or epstein-barr virus (ebv) infection * known history of hemophagocytic lymphohistiocytosis (hlh) or macrophage activation syndrome (mas) * acute or chronic hepatitis b virus (hbv) or hepatitis c virus (hcv) infection * human immunodeficiency virus (hiv) seropositivity * history of central nervous system (cns) myeloma disease * significant cardiovascular disease
project bidof - monovision by pairing bifocal and edof lens

Conditions: Cataract Senile

Summary: modern day cataract surgery isn't just a rehabilitative procedure anymore but rather aims at improving a patient's quality of life by reducing the need for spectacles in everyday life to a minimum. one way of achieving this goal is by using different lens technologies, such as a mono- or bifocal lens paired a lens with edof technology, as edof lenses provide an enhanced depth of focus by creating a single elongated focal point. as this method is well established, the aim of this study is to compare the monofocal/edof cohort to the bifocal/edof cohort and evaluate visual acuity and patient satisfaction for both combinations.


Eligibility criteria:
inclusion criteria: * age between 21 and 99 years * signed informed consent form * condition after cataract surgery exclusion criteria: * no signed informed consent form * laser treatment of the cornea * macular pathologies * corneal pathologies * irregular astigmatism * pregnancy
treatment and complication of bath puva in vitiligo

Conditions: Vitiligo

Summary: the purpose of this study is to determine whether bath puva are effective in treatment of vitiligo and what is the complication of bath puva in vitiligo.


Eligibility criteria:
inclusion criteria: * vitiligo exclusion criteria: * pregnancy

Keywords: bath puva
meditation therapy in improving anxiety and depression in cancer patients with psychosocial distress

Conditions: Anxiety; Depression; Malignant Neoplasm

Summary: this trial studies how well self-administered meditation therapy works in improving anxiety and depression in cancer patients who exhibit psychosocial distress. meditation therapy is a mind-body approach that uses a variety of techniques, such as deep breathing, sound, or movement, that may help to decrease distress and anxiety and enhance the health and quality of life of patients with cancer.

primary objectives: i. to determine the feasibility of having patients self-administer meditation recordings using a portable, computer-based program during a 2-week period. secondary objectives: i. assess the effect of self-administered meditation on anxiety, depression and other symptoms that are part of the edmonton symptom assessment scale (esas) questionnaire. ii. evaluate participant satisfaction with the meditation delivery and tracking program. iii. examine the association between the frequency of practice (number of sessions a day) and choice of length of practice (5, 10, or 15 minute sessions) and anxiety, depression and other patient reported outcomes. outline: patients are randomized to 1 of 2 groups. group i (meditation): patients watch a pre-recorded instructional meditation video via an ipod meditation app. patients then complete meditation exercises using the meditation app over 5-15 minutes once daily (qd) for up to 2 weeks. patients also complete questionnaires before and after meditation sessions and participate in an interview over 10 minutes. group ii (waitlist control): patients receive supportive care, such as access to social workers, support groups, spiritual care, or other patient services for up to 2 weeks. patients also complete questionnaires over 15-20 minutes and participate in an interview over 10 minutes.

Eligibility criteria:
inclusion criteria: * patients at md anderson with a cancer history who are either undergoing active treatment or who have completed treatment for their cancer * must understand and read english, sign a written informed consent, and follow protocol requirements * willing to come to md anderson main campus (texas medical center) for enrollment * patient self-reported esas psychological scale score (sum of anxiety and depression scores) between 4 and 11 (and/or) individual anxiety or depression score between 4 and 7 on a 0 to 10 numeric scale, where 10 is the worst possible * if on medication for anxiety, stable dose of medications for management of anxiety symptoms for at least six weeks prior to enrollment with no plans to change meditations in the subsequent four weeks. increases or decreases allowed within drug class, but changing drug class will make patient in-evaluable exclusion criteria: * diagnosis of a formal thought disorder (e.g., schizophrenia) * known history of a neurological and/or psychological disorder that in the physician's opinion may interfere with the patient's ability to cooperate with study procedures
impact - andhealth autoimmune research registry

Conditions: Arthritis, Rheumatoid; Arthritis, Psoriatic; Psoriasis; Ankylosing Spondylitis; Autoimmune Diseases

Summary: this is a patient research registry aimed at evaluating the effectiveness of a comprehensive, root-cause medical approach ("andhealth program") for autoimmune disorders. this approach involves a combination of pharmacological and non-pharmacological therapies offered under the care of a licensed physician with the support of health coaches. while protocol guidance is provided, the therapeutic approach is personalized to the individual needs of patients. the autoimmune disorders of focus in this registry include rheumatoid arthritis, psoriatic arthritis, psoriasis and ankylosing spondylitis. a variety of validated labs, patient-reported outcomes, and medication usage will be assessed among participating patients over a period of up to five years to evaluate the long-term effectiveness of this approach.


Eligibility criteria:
inclusion criteria: 1. adults 18 to 70 years of age 2. able to understand and write english 3. voluntarily consent to the study and understand its nature and purpose including potential risks and side effects 4. documented diagnosis and current use/recommendation for biologic or dmard medications to treat rheumatoid arthritis, psoriatic arthritis, psoriasis, or ankylosing spondylitis. exclusion criteria: 1. pregnant, breastfeeding, or planning to become pregnant in the next 12 months 2. advanced liver or kidney disease 3. previous organ transplant or awaiting organ transplant 4. actively being treated for cancer 5. poorly-controlled mental illness (i.e., schizophrenia, bipolar, current eating disorder) 6. has a terminal illness 7. current opioid use
personalized gi motility responses to diet

Conditions: Nutritional and Metabolic Diseases; Gastrointestinal Dysfunction; Cardiovascular Diseases; Dysbiosis

Summary: the goal of this randomized, crossover, clinical trial is to link: 1) gastrointestinal motility patterns induced by acute consumption of whole and refined grains, 2) enteric microbial production of bioactive metabolites, and 3) circulating postprandial appearance of metabolites important to cardiometabolic health including glucose, triglycerides, and cholesterol. participants will be asked to consume a smartpill monitoring device that records metrics of gastrointestinal motility in response to whole or refined grains, monitor cardiometabolic metabolties over an 8 hour postprandial window, and provide a fecal sample for microbiome-related analyses.


Eligibility criteria:
inclusion criteria: * healthy men and women exclusion criteria: physician-diagnosed: * diabetes mellitus * nutrient-malabsorption disorders * intestinal bowel syndrome (ibs) * intestinal bowel disease (ibd) * bleeding-related disorders * grain allergy * psychological disorders * stenosis * dysphasia history of: * bariatric surgery * gallbladder removal * eating disorders * antibiotic administration (within the past three months) * hormone therapy currently: * using statins * pregnant, lactating, or postmenopausal * taking oral hypoglycemic agents or insulin * ingesting prescription fiber * using cholesterol and bile acid absorption inhibitors * ingesting nutrition supplements, not including a daily multivitamin (i.e. herbs, tinctures, and extracts) •using recreational drugs or alcohol (within the past week) * taking anti-histamines * taking proton pump inhibitors * taking antacids

Keywords: dietary fiber gastrointestinal motility cardiometabolic microbiome